

AFibとACSを有する患者に対するアスピリンを用いない 2剤併用療法は最も安全である(Abstract 19-LB-19653)

AUGUSTUS: AFibとACSを有する患者に対するアピキサバンとP2Y12阻害薬の併用は最も有効であり有害事象が最も少ない

AUGUSTUS: Apixaban plus P2Y12 inhibitor most effective with fewest adverse events for patients with both AFib and ACS

心筋梗塞、脳卒中および血栓のリスクが高く、アピキサバンとクロピドグレルなどの抗血小板薬で治療された患者は、ワルファリンなどの古いタイプの抗凝固薬を投与された患者に比べ、出血および入院のリスクが有意に低かった、と American College of Cardiology's 68th Annual Scientific Session で発表された。さらに、アスピリンを併用せずクロピドグレルを投与された患者は出血リスクが47%低く、MI、脳卒中または血栓のイベントは増加しなかった。このスタディ結果は公表と同時に *New England Journal of Medicine* オンライン版に掲載された。

Full Text

Patients at high risk for myocardial infarction (MI), strokes and blood clots who were treated with a novel blood thinner (apixaban) and an antiplatelet drug such as clopidogrel had a significantly lower risk of bleeding and being hospitalized compared with patients who received an older blood-thinning medication such as warfarin, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. In addition, patients who received clopidogrel without concurrent aspirin, which has been standard for these patients, had an additional 47 percent reduction in bleeding events with no increase in MI, strokes or blood clots when compared with patients who received aspirin.

The lowest rates of bleeding, with no increase in deaths or hospitalizations, were seen in patients who did not receive aspirin and were treated with apixaban plus a drug such as clopidogrel. In addition to the significant reduction in risk for bleeding and lower rates of stroke, patients treated with these two medications had no increase in MIs or blood clots.

"We have shown that when it comes to treating this high-risk patient population, less may be more," said Renato D. Lopes, MD, PhD of the Duke Clinical Research Institute at Duke University School of Medicine in Durham, North Carolina, and the study's lead author. "Our findings show that the combination of apixaban and a drug such as clopidogrel—without aspirin—is the safest treatment regimen for this difficult-to-treat group of patients, without significantly increasing ischemic events such as myocardial infarctions (MI), strokes and blood clots. These results should reassure clinicians that it's okay not to treat most of these patients with aspirin."

Patients in the trial, known as AUGUSTUS, had both atrial fibrillation (AFib), heart failure and other heart complications, and acute coronary syndrome (ACS). ACS may take the form of an MI or unstable angina that may signal an imminent MI. Choosing the optimal treatment for patients with both AFib and ACS is challenging, Lopes said. These patients need to take a blood thinner to prevent stroke and blood clots, but blood thinners have not been shown to prevent blood clots in stents (stent thrombosis) and are usually not recommended for patients with ACS. Treatment with aspirin plus clopidogrel or a similar dual antiplatelet therapy (DAPT) has been shown to reduce heart attacks and stent thrombosis in patients with ACS but not stroke associated with AFib. Moreover, combining a blood thinner with DAPT increases the risk of potentially life-threatening bleeding.

Most AFib treatment trials have excluded patients with ACS, while most ACS treatment trials have excluded patients with AFib, Lopes said, creating a gap in researchers' understanding of how best to treat patients who have both conditions. Among the unanswered questions: whether a next-generation blood thinner such as apixaban is more effective than warfarin, the standard treatment, for reducing episodes of bleeding in this group of patients and whether these patients fare better if they take aspirin plus a medication such as clopidogrel in addition to a blood thinner.

The AUGUSTUS trial was designed to answer both questions. It is the first randomized, double-blinded, placebo-controlled trial to test the effect of withdrawing aspirin from the treatment regimen for a patient population at high risk for bleeding as well as for MIs, strokes and blood clots, Lopes said.

The trial enrolled 4,614 patients in 33 countries, including the United States, Canada, Mexico, the United Kingdom, and other countries in Europe, Asia and South America. Patients' median age was 70 years and 71 percent were men. All patients had AFib requiring long-term treatment with a blood thinner, had experienced a recent episode of ACS and/or were having a stent inserted in a blocked artery.

All the patients had an indication to take medications to reduce the risk of blood clots in the arteries by inhibiting platelets. More than 92 percent were taking clopidogrel at baseline; the rest were taking one of the similar drugs (e.g., prasugrel, ticagrelor).

Within 14 days of an ACS episode or stent insertion, patients underwent random assignment twice: first, to receive either apixaban or warfarin and, second, to receive either a daily baby aspirin or a matching placebo. The aspirin-or-placebo treatment assignments were double blinded, meaning that neither the patients nor their doctors knew who was receiving which treatment. The apixaban-or-warfarin treatment assignments were not blinded because of the need for patients taking warfarin to get regular blood tests to check the drug's effect on blood clotting.

All patients were treated for six months. This follow-up period was selected because most bleeding episodes, MIs, strokes and blood clots occur during the first six months after an ACS episode, insertion of a stent or initiation of a blood-thinning medication, Lopes said.

The trial's primary endpoint was major or clinically relevant nonmajor bleeding as defined by the International Society on Thrombosis and Haemostasis (ISTH). The ISTH definition includes bleeding that results in death; occurs in a critical organ; or results in hospitalization, medical treatment or surgery for bleeding or a change in the patient's anti-blood-clotting treatment. Secondary endpoints included a composite of death or hospitalization and a composite of death or stroke, MI, stent thrombosis or urgent treatment to unblock an artery.

Results for the primary safety endpoint showed that patients taking apixaban had a 31 percent reduction in risk compared with patients taking warfarin and that patients taking a placebo instead of aspirin had a 47 percent reduction in risk compared with those taking aspirin. The proportion of patients who had a bleeding episode was highest among patients treated with clopidogrel, warfarin and aspirin (18.5 percent), and lowest among those treated with clopidogrel, apixaban and placebo (7.3 percent).

The proportion of patients who died or were hospitalized was highest for patients treated with clopidogrel, warfarin and aspirin (27.5 percent) and lowest for those treated with clopidogrel, apixaban and placebo (22 percent). Patients treated with apixaban also had 50 percent lower risk of stroke compared with those taking warfarin.

A limitation of the study, Lopes said, is that it was not large enough to detect potential small differences in clinically important but rare outcomes such as stent thrombosis for individual patients.

The study was funded by Bristol-Myers Squibb and Pfizer, Inc.

It was simultaneously published online in the *New England Journal of Medicine* at the time of presentation.

ACC2019特集

[News01]
糖質制限ダイエットは心房細動に関連する

[News02]
フィットネスレベルが高いほど高齢者の寿命を延ばす可能性がある

[News03]
外科手術リスクの低い患者に対するTAVRは外科手術と同様に優れている

[News04]
二尖弁性大動脈弁狭窄に対する治療選択肢は開心術のみではない

[News05]
ベンパド酸は12週後のLDLコレステロールを低下させる

[News06]
AFibとACSを有する患者に対するアスピリンを用いない2剤併用療法は最も安全である

[News07]
生体吸収性エンベロープはデバイス関連感染症を減少させる

[News08]
ダバグリフロジンは駆出率の低下した患者に有益である

[News09]
ステント留置後の患者においてDAPTを中止することにより予後が改善する

[News10]
PCIにおける橈骨動脈アプローチと大腿動脈アプローチとは生存率に関しては同等である

[News11]
心内膜炎に対する抗菌薬の経口投与への切り替えは失敗ではない

[News12]
進行した心不全において新たなLVADは転帰をより良好にする

[News13]
高純度オメガ3製剤は心血管イベントを著明に減少させる

[News14]
閉鎖不全を有する弁の修復はQOLを改善する

[News15]
全ての心停止に対し緊急のインターベンションが必要なわけではない

[News16]
CardioMEMSセンサーは入院を半分以下に減少させる

[News17]
高齢者において降圧は脳損傷の悪化を予防する